BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21364371)

  • 1. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
    van Dyck CH; Schmitt FA; Olin JT;
    Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].
    Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M; Represa Veiga S
    Rev Esp Salud Publica; 2005; 79(6):665-72. PubMed ID: 16457058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
    Farlow MR
    Mayo Clin Proc; 2006 Oct; 81(10):1350-8. PubMed ID: 17036561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining treatment guidelines in Alzheimer's disease.
    Doody RS
    Geriatrics; 2005 Jun; Suppl():14-20. PubMed ID: 16025771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.
    Klinger T; Ibach B; Schoenknecht P; Kamleiter M; Silver G; Schroeder J; Mielke R
    Curr Med Res Opin; 2005 May; 21(5):723-32. PubMed ID: 15969871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are anti-dementia drugs worthwhile?].
    Lang CJ
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():85-9. PubMed ID: 17955784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.